We propose that new therapies that are more effective in lowering phytosterols, particularly in depleting stigmasterol from the body, represent a valuable therapeutic strategy for reducing residual risk of cardiovascular disease in the post-PCSK9 inhibitor era of tightly controlled cholesterol. The gene discussed is PCSK9; the disease is cardiovascular disorder.